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ABSTRACT
Objectives: To determine the feasibility of a trial of
patient-reported outcome measures (PROMs) for
monitoring primary care patients with depression.
Design: Partly individually randomised, partly cluster-
randomised controlled trial.
Setting: Nine general practices in Southern England.
Participants: 47 adults with new episodes of
depression: 22 intervention, 25 control.
Randomisation: Remote computerised sequence
generation and allocation.
Interventions: Patient Health Questionnaire, Distress
Thermometer Analogue Scale and PSYCHLOPS
problem profile for monitoring depression, following
diagnosis and at 10–35 days later. Feedback of scores
to patients was determined by practitioners.
Blinding: Non-blinded, using self-completed
measures.
Primary outcome: Beck Depression Inventory (BDI-II).
Secondary outcome measures: Work and Social
Adjustment Scale (WSAS), EuroQol Five-item, Five-level
(EQ-5D-5L) Scale for quality of life, modified Client
Service Receipt Inventory for costs, Medical Informant
Satisfaction Scale (MISS), qualitative interviews with 14
patients and 13 practice staff about feasibility and
acceptability of trial design.
Results: Three practices failed to recruit the target of six
patients in 12 months. Follow-up rates were intervention
patients: 18 (82%) at 12 weeks and 15 (68%) at
26 weeks; controls: 18 (72%) and 15 (60%),
respectively. At 12 weeks, mean BDI-II score was lower
among intervention group patients than controls by 5.8
points (95% CI −11.1 to −0.5), adjusted for baseline
differences and clustering. WSAS scores were not
significantly different. At 26 weeks, there were no
significant differences in symptoms, social functioning,
quality of life or costs, but mean satisfaction score was
higher among controls by 22.0 points (95% CI −40.7 to
−3.29). Intervention patients liked completing PROMs,
but were disappointed when practitioners did not use the
results to inform management.
Conclusions: PROMs may improve depression
outcome in the short term, even if PROM scores do not
inform practitioners’ management. Challenges in
recruiting and following up patients need addressing for
a definitive trial of relatively brief measures which can
potentially inform management. https://www.isrctn.com/
search?q=97492541
Trial registration number: ISRCTN 97492541; Pre-
results.
BACKGROUND
Depression is common and costly. The esti-
mated prevalence among adults in the UK is
11.1%, including major depressive disorder
in 3.3% and mixed depression and anxiety
in 7.8%.1 It can lead to chronic disability,
poor quality of life, suicide in some cases
and high levels of health service use and eco-
nomic costs. The King’s Fund have estimated
that 1.45 million people will have depression
in England by 2026, and total societal costs
will be £12.2 billion per year, including health-
care, social services and lost employment.2
The National Institute for Health and Care
Excellence (NICE) depression guidelines
recommend different interventions for
Strengths and limitations of this study
▪ Pragmatic trial with few exclusion criteria, readily
generalisable.
▪ Patients were randomly allocated with conceal-
ment of allocation from patients until after
informed consent had been obtained and base-
line measures completed.
▪ Patients, practitioners and assessors could not
be blinded to allocation.
▪ Self-report research outcome measures should
have prevented observer rating bias.
▪ Despite the small sample size, we did find a dif-
ference in the primary outcome.
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moderate to severe depression than for mild depres-
sion.3 However, general practitioner (GP) clinical assess-
ments of the severity of depression vary and are often
inaccurate when compared with validated measures.4 5
Consequently, some GPs do not accurately target treat-
ment to patients most likely to beneﬁt,6–8 reducing the
cost-effectiveness of treatment, which needs to be opti-
mised given the impact of depression.
As a result of these ﬁndings, NICE recommends that
health professionals consider using validated question-
naire measures of severity at diagnosis to help target
treatment.3 Between 2006 and 2013, the UK GP contract
Quality and Outcomes Framework (QOF) paid GPs to
use symptom questionnaires as part of their assessments
of depression severity at the outset of treatment for
patients with a new diagnosis.9 Symptom questionnaire
assessments at follow-up of treated patients were also
incentivised through the QOF between 2009 and 2013,
to promote follow-up reassessment.10
Some patients value using symptom questionnaires to
assess treatment effectiveness and monitor their pro-
gress,11 12 and some GPs also value them for monitoring
patients’ progress. The likelihood of antidepressant
treatment and/or referral for psychological therapy is
signiﬁcantly associated with higher symptom question-
naire scores at diagnosis,13 and decisions to change treat-
ment are signiﬁcantly associated with changes in scores
at follow-up.14
However, the use of symptom questionnaires is disliked
by some GPs, who worry they intrude in sensitive consul-
tations and undermine professional autonomy and,
doubting their validity, prefer using clinical judgement
to assess severity and response to treatment.11 15 In 2012,
a NICE-commissioned systematic review concluded that
the evidence supporting questionnaires was not strong
enough to require their use in QOF depression indica-
tors.16 Current QOF guidance suggests formal assess-
ment questionnaires can be used to measure severity at
reviews 10–56 days after diagnosis, but this is optional
rather than required to receive payments for the
reviews.17
The QOF depression symptom questionnaires are an
example of patient-reported outcome measures
(PROMs), the use of which has been promoted in
recent years to increase patient involvement in their own
care.18 A recent Cochrane systematic review of the use of
PROMs in the treatment of common mental health dis-
orders (CMHDs) including depression found some evi-
dence of beneﬁt for patients identiﬁed as having a lack
of improvement early on in treatment, but the research
was generally of low quality.19 More research is required,
particularly in primary care where most CMHDs are
treated.
If using symptom questionnaires and other PROMs is
beneﬁcial even to a modest extent, they are likely to be
cost-effective given their low cost, and the beneﬁts at a
population level would be considerable in public health
terms, given the high cost to the nation of depression.
Randomised trials of using PROMs to monitor patients’
progress in primary care are however needed to inform
practitioners deﬁnitively whether their use is beneﬁcial,
given their justiﬁable doubts about the validity of the
approach.
We decided a feasibility study was needed ﬁrst, to
determine whether practices in England would agree to
use PROMs with patients during consultations for the
assessment of depression at diagnosis and follow-up. It
was also needed to determine whether a trial rando-
mised at patient level would be preferable to cluster-
randomising whole practices, which might need a bigger
sample size, depending on the intracluster correlation
coefﬁcient (ICC) between practices, which could also be
estimated through a feasibility trial.
AIM
To test the feasibility of conducting a randomised con-
trolled of PROMs for monitoring outcomes for patients
with depression in primary care.
Objectives
A. To determine key elements of the best design for a
trial, including:
1. The willingness and ability of general practices to:
▸ recruit patients during consultations at which
depression is diagnosed
▸ recruit through mail-outs to patients recorded as
having consulted for depression
▸ be randomised to intervention or control arms
as whole practices (cluster design)
▸ have patients individually randomised to inter-
vention or control arms
2. The willingness of patients with depression to:
▸ complete PROMs in the intervention arm
▸ complete measures of symptoms, functioning,
quality of life and service use
3. Numbers of eligible patients found per practice
4. Rates of recruitment and follow-up
B. To test the feasibility and acceptability of administer-
ing the Patient Health Questionnaire (PHQ-9)20 for
depressive symptoms, Distress Thermometer Analogue
Scale21 and PSYCHLOPS individual problem proﬁle22
as PROMs for depression
C. To explore effects of the intervention on depressive
symptoms, social functioning, quality of life, satisfac-
tion and costs
D. To estimate the ICC for the primary outcome to use
in calculating the necessary increase in sample size
for a cluster-randomised full trial.
METHODS
Trial design
Parallel group, partly individually randomised, partly
cluster-randomised trial, with 1:1 allocation between
intervention and control arms.
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Participants
Group general practices in and around Southampton,
Southern England, were recruited through the National
Institute for Health Research (NIHR) Clinical Research
Network (CRN).
Eligibility criteria were adult patients aged 18 years
and above, diagnosed with a new episode of depression.
Exclusion criteria were previous treatment for depres-
sion within 12 months, comorbid dementia, psychosis,
substance misuse or serious suicidal ideation needing
urgent specialist referral. The diagnosis of a new episode
of depression and previous treatment for depression
were deﬁned by the participating GPs rather than
assessed independently, in keeping with the pragmatic
nature of the trial.
Where possible, patients who had been diagnosed
with a new episode of depression were recruited oppor-
tunistically during consultations by GPs and practice
nurses (PNs) and referred to the study team to discuss
taking part. Newly diagnosed patients were also identi-
ﬁed through medical record searches, designed to be
weekly, by practice administrative staff, mailed informa-
tion about the study and asked if they wished to discuss
taking part. Records were searched for 116 Read codes23
for depressive diagnoses and symptoms (see online
supplementary appendix 1 for a list of speciﬁc Read
codes).
Intervention
The intervention was the administration of the three
PROMs, the PHQ-920 for depressive symptoms, the
Distress Thermometer Analogue Scale for distress21 and
the PSYCHLOPS proﬁle rating of one or two problems
individual to the patient,22 administered as soon as pos-
sible after diagnosis, reviewed by the GP or PN and
repeated at a follow-up GP or PN consultation 10–
35 days later. Table 1 shows what each of the PROMs
measures, and the rationale for their inclusion.
Researchers visited patients willing to be contacted,
either at home or at their practices, sought informed
written consent, carried out baseline assessments and
administered the three PROMs to intervention group
patients, with a brief explanation of each measure and
further discussion of any questions on the PROMs
patients were unsure about. Patients completed the
PROMs on paper and were asked to book an appoint-
ment with their GP or PN within a week, or as soon as
possible, and to take the completed measures along, to
discuss the results. Patients were not routinely given
feedback on the meaning of the PROM scores by the
researcher: routine feedback of results was left to the
participating practitioners. If patients asked for immedi-
ate feedback, the researchers informed them only what
their PROM scores were in relation to the possible
maximum scores, and advised them to speak to their
GP/PN for further information and guidance.
Participating GPs and PNs were given up to half an
hour’s instruction on the meaning of the scores on the
three PROMs at the start of the study. They were asked
to take the PROM scores into account at their consulta-
tions with participating patients within days of comple-
tion of the ﬁrst set of PROMs. They were also asked to
provide the patients with another set of the three
PROMs to complete again immediately prior to
follow-up consultations 10–35 days later. Advice was
given on the meaning of scores on the PROMs at the
consultation following diagnosis and of changes in
scores between the ﬁrst and second follow-up consulta-
tions. See online supplementary appendix 2 for the
advice given about the meaning of PROM scores.
Table 1 Study patient-reported outcome measures (PROMs)
Measure What it measures Rationale for inclusion
Patient Health Questionnaire, nine-item
version (PHQ-9)20
Severity of depression using nine
questions covering diagnostic criteria
for major depression. Total scores
are categorised as minimal (1–4),
mild (5–9), moderate (10–14),
moderately severe (15–19) and
severe (20–27).
Validated in UK primary care24 and the
most commonly used symptom
questionnaire in UK general practice when
incentivised through the Quality and
Outcomes Framework.13
Distress thermometer single-item
question screen originally developed for
people with cancer21 but can measure
distress coming from any source
Visual Analogue Scale on which
patients indicate how distressed they
have been during the past week on a
scale of 0–10. Scores of 4 or more
indicate a significant level of distress
that should be investigated further.
A rapid indication of change in distress
level. Does not require English skills to
complete, unlike questionnaires.
PSYCHLOPS psychological outcomes
profile,22 a one-page three-item
self-report measure
Patient descriptions of their own
particular individual problem or two
problems, their ratings (0–5) of how
their problem(s) affect their daily
functioning, and their ratings (0–5) of
overall well-being.
Approved by the Plain English Campaign
and carries the ‘Crystal Mark’ for clarity.
Shown to be highly sensitive to change
during the course of psychotherapeutic
interventions.22
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Whether or not feedback on the results of the PROMs
was given by the practitioners to the patients, and any
treatment and further follow-up provided for depres-
sion, was left to the discretion of participating practi-
tioners for patients in intervention and control groups.
Control group patients did not complete any PROMs.
All patients completed the research outcome measures
(below) but were not given feedback on the results of
those assessments (see online supplementary appendix
3 for an overview of study intervention and control
procedures).
Assessments
Patients were recruited over a 12-month period and fol-
lowed up for 26 weeks each, with assessments at baseline,
12 and 26 weeks follow-up. Baseline measures included
sociodemographic details (age, gender, length of educa-
tion, employment, cohabitation), duration of symptoms,
previous history of depression, previous treatment and
the Generalised Anxiety Disorder (GAD-7)
Questionnaire for anxiety symptoms.25
Outcomes
The primary outcome measured at 12 and 26 weeks
follow-up was depressive symptoms on the Beck
Depression Inventory 2nd edition (BDI-II).26 Social
functioning on the Work and Social Adjustment Scale
(WSAS)27 and quality of life on the EuroQol Five-item,
Five-level (EQ-5D-5L) Scale28 were also measured at 12
and 26 weeks follow-up. At 26 weeks follow-up, use of ser-
vices was determined using a modiﬁed version of the
Client Services Receipt Inventory29 to allow calculation
of National Health Service (NHS) service costs, and
patient satisfaction was determined using the Medical
Informant Satisfaction Scale (MISS).30
Sample size
A formal sample size calculation was not performed, as
the aim was to explore effectiveness not to determine it
accurately. We aimed to obtain primary outcome data on
40 patients, 20 in each arm, which we judged would be
sufﬁcient to allow estimation of rates of recruitment and
follow-up, and of the variance in the primary outcome
measure the BDI-II, together with its ICC between prac-
tices, to inform a sample size calculation for the main
trial if a cluster-randomised design were to be chosen.
We estimated an average group practice could recruit
six patients in 12 months. This was based on the mean
number of patients per practice of 23 per year with a
new episode of depression found to have been assessed
using the QOF-incentivised PHQ-9 in a previous observa-
tional study14 and an assumption that around 25% of
diagnosed patients would consent to participate. (The
prevalence of depression is considerably higher,1 but we
aimed to recruit only patients with an incident episode
rather than all patients currently suffering from depres-
sion.) We further anticipated 15% would drop out of
follow-up based on a previous trial of antidepressants31
in primary care which meant we would need to recruit
48 patients from eight practices to obtain primary
outcome data on around 40 patients at follow-up.
Randomisation
Four of the practices were cluster randomised to inter-
vention or control arms, while in the remaining prac-
tices patients were individually randomised, in order to
explore the feasibility and acceptability of both methods.
Randomisation was carried by the study statistician (BS)
using computerised sequence generation. The research-
ers were aware of randomisation status for patients of
cluster-randomised practices. For individually rando-
mised patients, researchers telephoned the statistician
for allocation to intervention or control after obtaining
informed consent and carrying out baseline assessments.
Blinding
Patients, practitioners and researchers could not be
blinded to allocation given the nature of the interven-
tion. Self-report outcome measures were used to prevent
observer rating bias.
Analysis
Feasibility and acceptability were assessed through ana-
lysis of rates of recruitment, dropout and follow-up.
Patients rated the ease of completion of the measures
and time taken using 5-point Likert scales.
Differences at 12 and 26 weeks follow-up between inter-
vention and control patients in depressive symptoms and
social functioning were explored using a linear mixed
model adjusting for sociodemographic characteristics,
baseline depressive and anxiety symptoms, and for cluster-
ing by practice by including practice as a random effect.
Patient satisfaction, quality of life (in quality adjusted life
years (QALYs)) and costs over 26 weeks were also com-
pared between arms. The analysis included only patients
for whom we had outcome data (ie, complete cases).
The acceptability of trial procedures and chosen
PROMs was also explored through semistructured quali-
tative interviews with samples of participating patients
and health professionals, aiming to interview 15–20 of
each. Interviews were transcribed verbatim and analysed
using an inductive thematic analysis approach.32
The study was sponsored by the University of
Southampton.
RESULTS
Recruitment
Recruitment of practices and patients took place
between September 2014 and February 2016 inclusively,
and the 26-week follow-ups ended in September 2016.
Eight practices were recruited to the study in the ﬁrst
month as planned. Four of them were cluster rando-
mised to intervention or control arms, and in the
remaining practices, patients were individually rando-
mised. However, two of the original sample of practices
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failed to recruit any patients within the ﬁrst 3 months.
We therefore replaced these practices with two which
recruited patients more quickly, but due to slower than
desired recruitment among some of the other participat-
ing practices, we also agreed an amendment to our
protocol with the Research Ethics Committee (REC) to
recruit from a ninth practice, in order eventually to
achieve recruitment of 47 of our target of 48 patients.
One of the three replacement practices was cluster ran-
domised to replace a cluster-randomised practice which
had dropped out, and in the other two, patients were
individually randomised.
Three practices recruited six patients within 8 weeks,
while three failed to recruit six in a year, and three were
intermediate recruiters. Two of the three practices that
failed to recruit had individual mitigating circumstances.
One was recruited to the study late, with only a 1-month
time frame, so did well to recruit three patients.
Another decided to stop actively taking part in all
research and did not continue to recruit patients.
Feedback from the third practice suggested that greater
clarity on study eligibility criteria and guidance to
promote the study during consultations was needed to
prompt recruitment.
From the nine practices, a total of 78 patients agreed to
discuss participation, of whom 47 (60%) were rando-
mised (37 (79%) recruited in consultations and 10
(21%) through mail-outs). Practice logs showed that
fewer than 10% of patients identiﬁed as eligible and
mailed information about the study returned reply slips
indicating whether or not they were interested in partici-
pating. Of the 31 patients (40%) who were not recruited,
18 (23%) were uncontactable at baseline and 13 (17%)
declined after initial contact. The main reasons for
declining were no longer being interested in taking
part or having competing commitments (see ﬁgure 1,
consensus statement on reporting randomised trials
(CONSORT) ﬂow diagram of patient participation).
Baseline characteristics
Of the 47 recruited patients, 29 (62%) were women, 46
(98%) were white and 31 (66%) were in employment.
The average age was 44 years and average age of leaving
education 19. Study arms were reasonably well balanced
at baseline (table 2), except more intervention group
patients were married or cohabiting, and control patients’
scores for depression, social functioning and anxiety were
all slightly worse on average and less variable.
Follow-up rates
At 12 weeks, 18 of 22 intervention arm patients (82%)
and 18 of 25 controls (72%) completed the outcome
measures, and at 26 weeks, 15 (68%) and 15 (60%),
respectively (see CONSORT diagram, ﬁgure 1). Of those
followed up, 29 patients (81%) completed question-
naires face-to-face at 12 weeks and 26 (87%) at 26 weeks,
the rest completing them only after further follow-up by
post (19% at 12 weeks and 13% at 26). No patients
proved contactable to complete outcome measures over
the telephone.
Outcomes
Outcome scores at baseline, 12 and 26 weeks follow-up
are shown in table 3. At 12 weeks, the intervention
group adjusted mean score for depressive symptoms on
the BDI-II was signiﬁcantly lower than the control group
by 5.8 points (95% CI −11.1 to −0.5) after adjusting for
baseline depression scores, anxiety, sociodemographics,
psychotropic medication use and clustering by practice.
Adjusted mean score on the WSAS at 12 weeks was lower
(better) in the intervention group than the controls by a
mean of 3.0 points, which was not statistically signiﬁcant
(95% CI −7.3 to 1.3).
At 26 weeks, there were no signiﬁcant differences
between the groups in symptoms or social functioning
(adjusted mean BDI-II was slightly worse in intervention
arm by 2.5 points (95% CI −1.7 to 6.7); adjusted mean
WSAS was lower by 0.3 points (95% CI −5.2 to 4.6)).
However, the adjusted mean MISS satisfaction score was
22.0 points higher in the control group (95% CI −40.7
to −3.29).
Baseline EQ-5D-5L quality of life scores were similar
among intervention and control group patients (table 3).
Scores were improved at 12 weeks for both groups
although slightly higher among intervention patients
than controls, and scores went down again at 26 weeks
among controls.
The mean QALY gain over 26 weeks was 0.382 (SD
0.046) for intervention patients and 0.336 (0.132) for con-
trols, giving a non-signiﬁcant difference of 0.047 (95% CI
−0.036 to 0.129). Mean depression-related NHS service
costs per patient over 26 weeks were similar: control arm
£216 (95% CI £135, £297), intervention arm £231 (£129,
£332), including £16 per patient for an estimated 5 min
GPs or PNs spent dealing with PROM results.
Intracluster correlation coefficients
There was no evidence in this sample of clustering by
practice for the BDI-II or WSAS: the ICC was zero at
baseline for both. After controlling for baseline and ran-
domisation group, the ICC for the BDI-II at 12 weeks
was 0.03.
Ease of completion of outcome measures
On average, participants rated the BDI-II, WSAS and
GAD-7 as easy to use and the time taken was under
5 min for each. Ease of completion scores: mean (SD)
where 1=not at all easy and 5=very easy: BDI-II 4.29
(0.94), WSAS 4.38 (0.88) and GAD-7 4.38 (0.83). Time
taken (minutes): median (IQR): BDI-II 4 (3,5); WSAS
1.5 (1,3); and GAD-7 2 (1,2).
Qualitative interviews with patients and practice staff
The full qualitative analysis and illustrative quotes from
participants will be published separately. We present a
brief summary only in this paper.
Kendrick T, et al. BMJ Open 2017;7:e015266. doi:10.1136/bmjopen-2016-015266 5
Open Access
Fourteen patients were interviewed. Overall, in rela-
tion to the feasibility of the study, patients were happy to
be randomised (even when randomised to the control
arm), were supportive of the use of PROMS (seeing
potential beneﬁts for understanding their illness) and
reported them relatively easy and quick to complete.
There were some difﬁculties found in discussing the
results of PROMS with their practitioners which would
need attention in a deﬁnitive trial. Some were unable to
see the same practitioner for follow-up, and some
expressed disappointment at not having feedback on the
PROM scores from participating practitioners. Some
would have liked a record of changes in scores over time
to show their progress.
Interviews were carried out with 10 GPs, one PN and
two practice managers. In relation to feasibility
practitioners overall considered the use of PROMS to be
feasible. Positive feedback on using PROMs included:
help with communication, encouraging patients to feed
back on symptoms, feel listened to and taken seriously
(particularly the PSYCHLOPS); help with treatment
planning, conﬁrming decisions, and measuring progress;
providing structure in a consultation which could save
time; and not missing anything (especially the PHQ-9).
Negative feedback included: PROMS are too simplistic
(especially the Distress Thermometer), could be difﬁcult
for patients to complete (due to insufﬁcient health liter-
acy, sensitive questions or wanting to give the ‘correct’
answer), take time to complete in consultations and may
depersonalise interactions. Important areas that would
need to be improved to smooth their use in practice
included further clariﬁcation of patient inclusion
Figure 1 CONSORT flow diagram of patient participation.
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criteria, choosing measures that are easy for patients to
complete, and more guidance on what to do with the
PROM results once completed.
Methodological changes
Several changes were needed to overcome difﬁculties in
recruiting and following up patients.
As response rates to the practice mail-outs were lower
than 10%, we obtained ethics approval to send a revised
patient information leaﬂet which used varied font sizes
and coloured text to be more eye-catching, and for PNs
to telephone non-responding participants 2 weeks after
mail-outs to follow them up more actively (this did not
apply to those who had responded to say they were not
interested, only those who had not responded at all).
However, in the event, the telephone calls did not yield
any more participants.
The follow-up research assessments were originally
intended to be completed face to face, but we obtained
ethics approval to send the research assessment ques-
tionnaires by post if patients failed to attend follow-up
after two requests. We also obtained approval to send
patients a £10 high street shopping gift voucher with the
follow-up questionnaires sent by post. These changes
between them helped improve follow-up rates by around
10%.
Another change was approved to facilitate active
follow-up of non-responding patients. If they did not
complete follow-up questionnaires in person or by post,
the study team was permitted to try to contact them and
complete the primary outcome measure (BDI-II), and
two other key outcome measures (WSAS and EQ-5D-5L),
over the telephone. However, in the event, no non-
responders could be reached by telephone.
Table 2 Baseline characteristics
Characteristic Control patients (n=25) Intervention patients (n=22)
Female 16 (64.0%) 13 (59.0%)
Age (mean (SD)) 43.1 (17.1) 44.7 (18.5)
White ethnic group 24 (96.0%) 22 (100%)
Marital status
Married/cohabiting 6 (24.0%) 12 (54.5%)
Widowed/separated/divorced 8 (32.0%) 6 (27.3%)
Single 11 (44.0%) 4 (18.2%)
Any dependents at home 9 (36.0%) 7 (31.8%)
Age left education 18.6 (5.3) 18.8 (3.4)
Economic position
Full-time/part-time work 17 (68.0%) 14 (63.6%)
Sick/disabled 2 (8.0%) 1 (4.6%)
Unemployed 1 (4.0%) 1 (4.6%)
Retired/student/homemaker 5 (20.0%) 5 (22.7%)
Other 0 1 (4.6%)
BDI-II total score, mean (SD) 26.92 (7.93) 23.90 (11.92)
WSAS total score, mean (SD) 21.88 (9.37) 18.13 (10.00)
GAD-7 total score, mean (SD) 14.32 (5.27) 11.64 (5.83)
BDI-II, Beck Depression Inventory, 2nd edition;24 GAD-7, Generalised Anxiety Disorder Scale;23 WSAS, Work and Social Adjustment Scale.25
Table 3 Outcome measures at baseline and follow-up
Control group Intervention group
Measures
Baseline
(n=25)
12 weeks
(n=18)
26 weeks
(n=15)
Baseline
(n=22)
12 weeks
(n=18)
26 weeks
(n=15)
Depression
(BDI-II)
Mean (SD) 26.92 (7.93) 19.22 (11.62) 15.53 (10.04) 23.90 (11.92) 12.00 (8.93) 14.13 (12.54)
Social
functioning
(WSAS)
Mean (SD) 21.88 (9.37) 14.89 (9.30) 14.93 (10.79) 18.13 (10.00) 10.94 (8.12) 12.07 (11.35)
Anxiety (GAD-7) Mean (SD) 14.32 (5.27) – – 11.64 (5.83) – –
Quality of life
(EQ-5D-5L)
Mean (SD) 0.624 (0.284) 0.698 (0.246) 0.674 (0.299) 0.633 (0.242) 0.759 (0.105) 0.764 (0.158)
Satisfaction
(MISS)
Mean (SD) – – 148.93 (34.19) – – 137.93 (34.74)
BDI-II, Beck Depression Inventory, 2nd edition;24 EQ-5D-5L, EuroQol Quality of Life Scale;26 GAD-7, Generalised Anxiety Disorder Scale;23
MISS, Medical Informant Satisfaction Scale;28 WSAS, Work and Social Adjustment Scale.25
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Finally, approval was given for an additional practice
administrative staff review of the medical records of
recruited participants at the end of their participation,
as we were able to gather only limited information on
service use through the patient questionnaires. These
record reviews provided extra information on prescribed
medication, number of visits to GPs, PNs and community-
based staff, secondary care contacts, hospital admissions
and length of hospitalisation where appropriate.
DISCUSSION
Principal findings
It is feasible to carry out a randomised trial of PROMs
for the assessment and follow-up of depression in
primary care in England, although recruitment rates
and follow-up rates, particularly in the control arm,
would need improving signiﬁcantly for a larger, deﬁni-
tive trial. Intervention arm patients were happy to com-
plete the PROMs and research outcome questionnaires
and valued seeing the results. Differences between arms
suggest PROMs may reduce depressive symptoms,
yet also reduce patient satisfaction, perhaps because GPs
appeared not to value using PROM results to inﬂuence
management.
Strengths and limitations
The trial was pragmatic, with few exclusion criteria, and
readily generalisable to UK primary care, although the
small number of patients recruited in some of the prac-
tices raises the question of how representative the
sample was of all patients with new episodes of depres-
sion. Practices were able to recruit patients in GP/PN
consultations and through staff mail-outs to patients, but
two practices had to be dropped because of non-
recruitment after several months, and difﬁculties in
recruitment in other practices meant we recruited only
47 of the target of 48 patients.
Patients were randomly allocated to intervention or
control, with concealment of allocation from patients
until after informed consent had been obtained and
baseline measures had been completed. However
patients, practitioners and assessors could not be
blinded to allocation during the trial given the nature of
the intervention, although the use of self-report research
outcome measures should have prevented observer
rating bias.
The study was necessarily small in keeping with testing
feasibility, but in spite of this, we did ﬁnd a difference in
the primary outcome measure between arms at 12 weeks
follow-up, favouring the intervention. The adjusted dif-
ference between arms at 12 weeks as a percentage of the
score in the control group was 5.8/19.22=30.1%, which
is greater than the minimal clinically important differ-
ence (MCID) of a 17.5% reduction in scores from base-
line found to correspond to patients’ global reports of
signiﬁcant improvement.33 We did not determine how
many practitioners actually gave feedback on the PROMs
to their patients, but our patient interviews suggest not
all practitioners did. This might have inﬂuenced the
clinical outcome of the study, yet some beneﬁt was iden-
tiﬁed nevertheless.
Comparison with other studies
The results are in keeping with a US primary care-based
controlled trial of feeding back PHQ-9 scores to family
practitioners at diagnosis and follow-up, which demon-
strated signiﬁcantly improved patient outcomes over 6
months.34 The difference in outcome could not be
explained in terms of any signiﬁcant differences in man-
agement, but the beneﬁts of feeding back scores seemed
to arise from increasing patients’ awareness of their
symptoms and their ability to report relevant changes.35
That may explain why our patients may have derived
beneﬁt from using PROMs even when their GPs did not
seem to use the results to inform their care.
Implications for clinicians, policymakers and research
The implications are mainly for the design of a deﬁni-
tive trial rather than for practice at this stage, although
clinicians, policymakers and research funders might be
persuaded of the need for a more deﬁnitive trial on the
basis that short-term differences in outcome favouring
the use of PROMs were identiﬁed even in this small
sample.
To facilitate recruitment, and ensure as representative
a sample of patients as possible, a deﬁnitive trial should
aim to recruit more patients per practice from a smaller
number of more committed practices, rather than fewer
patients each from a larger number of practices.
Depressed patients are often viewed as in need of pro-
tection by GPs, who may feel introducing research is
intrusive.36 A lack of skills in introducing research could
be addressed through more training in a smaller group
of practices.
Follow-up at 12 weeks of 82% was sufﬁcient in the
intervention arm, but needs to be improved from 72%
in the control arm, and follow-up at 26 weeks needs to
be improved from 68% and 60%, respectively, through
taking steps to maintain better contact with patients,
obtaining mobile phone numbers, postal and email
addresses, and permission to post, text, telephone or
email them, as a signiﬁcant proportion failed to meet
face-to-face or complete and return the measures sent
by post. Participating practitioners should also be
trained to remind patients of their involvement in the
study when they attend review appointments. It is pos-
sible that some of the apparent beneﬁt of the interven-
tion was due to the extra attention patients received, so
it is important to have similar follow-up rates in the two
arms.
Current demands on practices, and the expansion of
less than full-time working, make it increasingly difﬁcult
to provide continuity of care, which may explain why
participating patients sometimes found it difﬁcult to get
follow-up appointments with the same GP. Therefore, it
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will be important to recruit practices where all GPs and
PNs in the practice agree to be involved in the study and
to be trained in recruiting, consenting and following up
all eligible patients, and looking at the results of PROMs
for all those in the intervention arm. In a deﬁnitive trial,
practices should be cluster randomised to streamline
recruitment and follow-up, so all patients in each are
treated the same, by whichever GP or PN they see.
Cluster randomisation tends to require a larger
sample due to clustering by practice (the design
effect), although the increase in sample size necessary
appears likely to be small based on this study. There
was no evidence of clustering at baseline, but the study
may not have been large enough to permit an accurate
estimation of the true value of the ICC and it would
be sensible in a larger trial to make an allowance for
clustering. After controlling for baseline and random-
isation group, the ICC for the BDI-II at 12 weeks was
0.03. The ICC for the BDI-II from a previous trial of
antidepressants for mild to moderate depression in
primary care was 0.02;31 therefore, an ICC of 0.03
might be appropriate to use to calculate the design
effect if the deﬁnitive trial is cluster randomised. This
is a relatively small ICC, but if a smaller number of
practices each recruiting more patients is recruited, the
design effect will be greater as it increases with increas-
ing cluster size.
Practice logs and recruitment rates in the better
recruiting practices show the numbers of eligible
patients per group practice will allow for more than six
patients to be recruited per year, given greater commit-
ment. Having a relatively smaller number of practices
recruit more patients each will be more efﬁcient in
terms of travel to practices by the research team, and
allow greater contact to be maintained with participating
staff in each, to optimise practice commitment.
Administration of PROMs needs to be streamlined,
and GPs provided with more guidance on how to assess
the results, to avoid disappointing patients by not using
the PROMs to inform care. Patients may beneﬁt from
being provided with a record of their PROM scores so
they can monitor their progress.
The study team needs to spend more time at partici-
pating practices training them in the recruitment
process and assisting them with setting up database
searches. Practices should complete a trial recruiting
period to assess their commitment, and practice
research costs should be reimbursed on a per-patient/
per-mail-out basis rather than paying them a lump sum
at the beginning of the trial, to incentivise recruitment.
Conclusions
Even in this small sample, the ﬁndings suggest that the
use of PROMs may be beneﬁcial in the short term,
although maybe not in the longer term. It provides
support for our plan to take forward a larger, deﬁnitive
trial. Before we proceed however, we need to do some
more work with potential participants, to identify the
most promising PROM. Given that some practitioners
found them time consuming and wanted more guidance
on how to take account of the results in their treatment
decisions, encouraging more practitioners to use PROMs
requires identifying relatively brief measures which can
potentially change management.
Twitter Follow Rachel Ryves @rachelryves, Christopher Dowrick @cfd1951
and Tony Kendric k@tony_kendrick
Contributors TK, BS, GML, AWAG, LY, CD, GL and MM made substantial
contributions to the conception or design of the work. RR, SW and SZ made
substantial contributions to the acquisition, analysis and interpretation of data.
All authors contributed to drafting the work and revising it critically for
important intellectual content, and all approved the final version submitted. All
authors agree to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
Funding National Institute for Health Research (NIHR) Research for Patient
Benefit (RfPB) Programme (grant number PB-PG-0613-31004).
Disclaimer The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health.
Competing interests All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors
had financial support from the NIHR Research for Patient Benefit Programme
for the submitted work.
Ethics approval The study was approved by the NHS Research Ethics
Committee (REC) South Central—Oxford A on 28 July 2014 (reference
number 14/SC/1067).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement We agree to make the relevant anonymised
patient-level data available on reasonable request.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. McManus S, Bebbington P, Jenkins R, Brugha T. eds. Mental health
and wellbeing in England: Adult Psychiatric Morbidity Survey 2014.
Leeds: NHS Digital, 2016.
2. McCrone P, Dhanasiri S, Patel A, et al. Paying the price: the cost of
mental health care in England to 2026. London: King’s Fund, 2008.
3. National Institute for Health and Clinical Excellence. Depression.
The treatment and management of depression in adults. CG90.
London: NICE, 2009.
4. Dowrick C. Case or continuum? Analysing general practitioners’
ability to treat depression. Primary Care Psychiatry 1995;1:255–7.
5. Thompson C, Kinmonth AL, Stevens L, et al. Effects of a
clinical-practice guideline and practice based education on detection
and outcome of depression in primary care: Hampshire Depression
Project randomised controlled trial. Lancet 2000;355:185–91.
6. Kendrick T, Stevens L, Bryant A, et al. Hampshire Depression
Project: changes in the process of care and cost consequences.
Br J Gen Pract 2001;51:911–13.
7. Kessler D, Bennewith O, Lewis G, et al. Detection of depression and
anxiety in primary care: follow-up study. BMJ 2002;325:1016–7.
8. Kendrick T, King F, Albertella L, et al. GP treatment decisions for
patients with depression: an observational study. Br J Gen Pract
2005;55:280–6.
9. BMA, NHS Employers. Revisions to the GMS contract 2006/07.
London: Delivering investment in general practice, 2006.
10. BMA, NHS Employers. Revisions to the Quality and Outcomes
Framework 2009/10. London: British Medical Association, 2009.
11. Dowrick C, Leydon GM, McBride A, et al. Patients’ and doctors’
views on depression severity questionnaires incentivised in UK
Kendrick T, et al. BMJ Open 2017;7:e015266. doi:10.1136/bmjopen-2016-015266 9
Open Access
quality and outcomes framework: qualitative study. BMJ
2009;338:b663.
12. Malpass A, Shaw A, Kessler D, et al. Concordance between PHQ-9
scores and patients’ experiences of depression: a mixed methods
study. Br J Gen Pract 2010;60:e231–8
13. Kendrick T, Dowrick C, McBride A, et al. Management of depression
in UK general practice in relation to scores on depression severity
questionnaires: analysis of medical record data. BMJ 2009;338:b750.
14. Moore M, Ali S, Stuart B, et al. Depression management in primary
care: an observational study of management changes related to
PHQ-9 score for depression monitoring. Br J Gen Pract 2012;62:
e451–7.
15. Leydon GM, Dowrick CF, McBride AS, et al. Questionnaire severity
measures for depression: a threat to the doctor–patient relationship?
Br J Gen Pract 2011;61:117–23.
16. Shaw EJ, Sutcliffe D, Lacey T, et al. Assessing depression
severity using the UK Quality and Outcomes Framework
depression indicators: a systematic review. Br J Gen Pract
2013;63:e309–17.
17. BMA, NHS Employers and NHS England, 2016. 2016/17
General Medical Services contract Quality and Outcomes
Framework (QOF). Guidance for GMS contract 2016/17. NHS
Confederation (Employers). http://www.nhsemployers.org/-/
media/Employers/Documents/Primary%20care%20contracts/
QOF/2016-17/2016-17%20QOF%20guidance%20documents.pdf
18. Black N. Patient reported outcome measures could help transform
healthcare. BMJ 2013;346:f167.
19. Kendrick T, El-Gohary M, Stuart B, et al. Routine use of patient
reported outcome measures (PROMs) for improving treatment of
common mental health disorders in adults. Cochrane Database Syst
Rev 2016;7:CD011119.
20. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief
depression measure. J Gen Intern Med 2001;16:606–13.
21. Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for
psychologic distress in men with prostate carcinoma. Cancer
1998;82:1904–8.
22. Ashworth M, Kordowicz M, Schofield S. ‘PSYCHLOPS’
(Psychological Outcome Profiles): an outcome measure. Integrating
Science and Practice 2012;2:36–9.
23. Health & Social Care Information Centre, 2015. http://www.hscic.gov.
uk/data/uktc/readcodes
24. Gilbody S, Richards D, Barkham M. Diagnosing depression in
primary care using self-completed instruments: UK validation of
PHQ–9 and CORE–OM. Br J Gen Pract 2007;57:650–2.
25. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for
assessing generalized anxiety disorder: the GAD-7. Arch Intern Med
2006;166:1092–7.
26. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression
Inventory-II. San Antonio, TX, Psychological Corporation, 1996.
27. Mundt JC, Marks IM, Shear MK, et al. The work and social
adjustment scale: a simple measure of impairment in functioning.
Br J Psychiatry 2002;180:461–4.
28. EuroQol Group. EuroQol-a new facility for the measurement of
health-related quality of life. Health Policy 1990;16:199–208.
29. Beecham J, Knapp, M. Costing psychiatric interventions. In:
Thornicroft G, Brewin C, Wing J, eds. Measuring mental health
needs London: Gaskell, 1992:163–83.
30. Meakin R, Weinman J. The ‘Medical Interview Satisfaction Scale’
(MISS-21) adapted for British general practice. Fam Pract
2002;19:257–63.
31. Kendrick T, Chatwin J, Dowrick C, et al. Randomised controlled trial
to determine the clinical and cost-effectiveness of selective serotonin
reuptake inhibitors plus supportive care, versus supportive care
alone, for mild to moderate depression with somatic symptoms in
primary care. The THREAD (THREshold for AntiDepressant
response) study. Health Technol Assess 2009;13:iii–iv, ix-xi, 1-159.
32. Braun V, Clarke V. Using thematic analysis in psychology.
Qualitative Research in Psychology 2006;3:77–101.
33. Button KS, Kounali D, Thomas L, et al. Minimal clinically important
difference on the Beck Depression Inventory-II according to the
patient’s perspective. Psychol Med 2015;45:3269–79
34. Yeung AS, Jing Y, Brenneman SK, et al. Clinical Outcomes in
Measurement based Treatment (COMET): a trial of depression
monitoring and feedback to primary care physicians. Depress
Anxiety 2012;29:865–73.
35. Chang TE, Jing Y, Yeung AS, et al. Effect of communicating
depression severity on physician prescribing patterns: findings from
the Clinical Outcomes in Measurement-based Treatment (COMET)
trial. Gen Hosp Psychiatry 2012;34:105–12.
36. Mason V, Shaw A, Wiles N, et al. GPs’ experiences of primary care
mental health research: a qualitative study of the barriers to
recruitment. Fam Pract 2007;24:518–25.
10 Kendrick T, et al. BMJ Open 2017;7:e015266. doi:10.1136/bmjopen-2016-015266
Open Access
